182 related articles for article (PubMed ID: 17133098)
1. Diagnosis and treatment of hypereosinophilic syndromes.
Fletcher S; Bain B
Curr Opin Hematol; 2007 Jan; 14(1):37-42. PubMed ID: 17133098
[TBL] [Abstract][Full Text] [Related]
2. The hypereosinophilic syndrome: fluorescence in situ hybridization detects the del(4)(q12)-FIP1L1/PDGFRA but not genomic rearrangements of other tyrosine kinases.
La Starza R; Specchia G; Cuneo A; Beacci D; Nozzoli C; Luciano L; Aventin A; Sambani C; Testoni N; Foppoli M; Invernizzi R; Marynen P; Martelli MF; Mecucci C
Haematologica; 2005 May; 90(5):596-601. PubMed ID: 15921374
[TBL] [Abstract][Full Text] [Related]
3. Hypereosinophilic syndrome: diagnosis and treatment.
Peros-Golubicić T; Smojver-Jezek S
Curr Opin Pulm Med; 2007 Sep; 13(5):422-7. PubMed ID: 17940488
[TBL] [Abstract][Full Text] [Related]
4. Novel approaches to therapy of hypereosinophilic syndromes.
Simon HU; Cools J
Immunol Allergy Clin North Am; 2007 Aug; 27(3):519-27. PubMed ID: 17868862
[TBL] [Abstract][Full Text] [Related]
5. [Efficiency of imatinib in polyserositis revealing a FIP1L1-PDGFRA-negative hypereosinophilic syndrome].
Green L; Kahn JE; Dufour JF; Le Scanff J; Charhon A; Broussolle C; Sève P
Rev Med Interne; 2010 Apr; 31(4):305-8. PubMed ID: 20167399
[TBL] [Abstract][Full Text] [Related]
6. [Hematological disorders and hypereosinophilias].
Malfuson JV; Fagot T; Konopacki J; Mangouka L; Souleau B; de Revel T
Rev Med Interne; 2009 Apr; 30(4):322-30. PubMed ID: 19201511
[TBL] [Abstract][Full Text] [Related]
7. Relationship between idiopathic hypereosinophilic syndrome, eosinophilic leukemia, and systemic mastocytosis.
Bain BJ
Am J Hematol; 2004 Sep; 77(1):82-5. PubMed ID: 15307112
[TBL] [Abstract][Full Text] [Related]
8. [A man with oral ulcers caused by hypereosinophilic syndrome and a good response to the tyrosine-kinase inhibitor imatinib].
Verstappen MC; Mattijssen V; van der Reijden BA; van der Heijden AJ; Wahab PJ; de Vries RA
Ned Tijdschr Geneeskd; 2006 May; 150(21):1188-92. PubMed ID: 16768284
[TBL] [Abstract][Full Text] [Related]
9. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome.
Cools J; DeAngelo DJ; Gotlib J; Stover EH; Legare RD; Cortes J; Kutok J; Clark J; Galinsky I; Griffin JD; Cross NC; Tefferi A; Malone J; Alam R; Schrier SL; Schmid J; Rose M; Vandenberghe P; Verhoef G; Boogaerts M; Wlodarska I; Kantarjian H; Marynen P; Coutre SE; Stone R; Gilliland DG
N Engl J Med; 2003 Mar; 348(13):1201-14. PubMed ID: 12660384
[TBL] [Abstract][Full Text] [Related]
10. Targeted treatment of hypereosinophilic syndromes and chronic eosinophilic leukemias with imatinib mesylate.
Coutré S; Gotlib J
Semin Cancer Biol; 2004 Feb; 14(1):23-31. PubMed ID: 14757533
[TBL] [Abstract][Full Text] [Related]
11. Diagnostic and therapeutic management in patients with hypereosinophilic syndromes.
Helbig G; Kyrcz-Krzemień S
Pol Arch Med Wewn; 2011; 121(1-2):44-52. PubMed ID: 21346698
[TBL] [Abstract][Full Text] [Related]
12. Targeted treatment of hypereosinophilic syndromes and chronic eosinophilic leukemias with imatinib mesylate.
Coutré S; Gotlib J
Semin Cancer Biol; 2004 Aug; 14(4):307-15. PubMed ID: 15305431
[TBL] [Abstract][Full Text] [Related]
13. Successful treatment of idiopathic hypereosinophilic syndrome with imatinib mesylate: a case report.
Tan D; Hwang W; Ng HJ; Goh YT; Tan P
Int J Hematol; 2004 Jul; 80(1):75-7. PubMed ID: 15293573
[TBL] [Abstract][Full Text] [Related]
14. [Idiopathic hypereosinophilic syndrome: toward a new molecular-targeted therapy and a new cytomorphological and molecular definition].
Moles MP; Landry J; Roche-Lestienne C; Godon A; Schmidt-Tanguy A; Gardembas M; Le Clech C; Verret JL; Zandecki M; Blanchet O
Ann Biol Clin (Paris); 2005; 63(3):317-22. PubMed ID: 15951264
[TBL] [Abstract][Full Text] [Related]
15. [Hypereosinophilic syndrome--recent developments in diagnosis and treatment].
Hellmich B; Holl-Ulrich K; Gross WL
Dtsch Med Wochenschr; 2007 Sep; 132(37):1892-6. PubMed ID: 17823882
[TBL] [Abstract][Full Text] [Related]
16. [Efficacy of imatinib in FIP1L1-PDGFRA positive hypereosinophilic syndrome].
Menif S; Ben Romdhane N; Hafsia R
Rev Med Interne; 2008 Jan; 29(1):65-7. PubMed ID: 18036706
[TBL] [Abstract][Full Text] [Related]
17. World Health Organization-defined eosinophilic disorders: 2014 update on diagnosis, risk stratification, and management.
Gotlib J
Am J Hematol; 2014 Mar; 89(3):325-37. PubMed ID: 24577808
[TBL] [Abstract][Full Text] [Related]
18. [Durable efficacity and remission after treatment with imatinib mesylate for FIP1L1-PDGFRA transcript negative associated eosinophilic cardiomyopathy].
Sekkach Y; Mekouar F; Jira M; Elqatni M; Elomri N; Fatihi J; Badaoui M; Hammi S; Smaali J; El Khattabi A; Amezyane T; Abouzahir A; Ghafir D
Ann Pharm Fr; 2011 Sep; 69(5):277-81. PubMed ID: 21924129
[TBL] [Abstract][Full Text] [Related]
19. Anti-IL-5 and hypereosinophilic syndromes.
Sutton SA; Assa'ad AH; Rothenberg ME
Clin Immunol; 2005 Apr; 115(1):51-60. PubMed ID: 15870021
[TBL] [Abstract][Full Text] [Related]
20. Cessation of imatinib mesylate may lead to sustained hematologic and molecular remission in FIP1L1-PDGFRA-mutated hypereosinophilic syndrome.
Helbig G; Kyrcz-Krzemień S
Am J Hematol; 2014 Jan; 89(1):115. PubMed ID: 24009127
[No Abstract] [Full Text] [Related]
[Next] [New Search]
